IIdiopathic multicentric Castleman disease (iMCD) is a hematologic illness involving cytokine-induced lymphoproliferation, systemic inflammation, cytopenias and life-threatening multi-organ dysfunction. No targeted therapies currently exist for this disease, and the only drug approved by the US Food and Drug Administration is effective in just one third of patients.
In this webinar, David Fajgenbaum, MD, MBA, MSc, ‒ who has a diagnosis of iMCD ‒ will discuss:
- His experience living with the disease
- The discovery of a novel therapeutic target
- How proteomic data generated from serum samples was used to identify novel biomarkers
